Last reviewed · How we verify
Placebo (tablets per os)
Placebo produces no pharmacological effect and serves as an inert control in clinical trials.
Placebo produces no pharmacological effect and serves as an inert control in clinical trials. Used for Control arm in phase 3 clinical trials (specific indication depends on parent trial).
At a glance
| Generic name | Placebo (tablets per os) |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is a pharmaceutical formulation containing no active ingredient. It is used in randomized controlled trials to establish baseline efficacy and safety by comparison with active drug treatment, allowing researchers to distinguish true drug effects from placebo response and natural disease progression.
Approved indications
- Control arm in phase 3 clinical trials (specific indication depends on parent trial)
Common side effects
- Placebo response (symptom improvement without active drug)
- Adverse events attributable to natural disease progression or unrelated causes
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (PHASE3)
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). (PHASE2, PHASE3)
- A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease (PHASE3)
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis (PHASE3)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |